Replies to post #554 on Trillium Therapeutics Inc (TRIL)

[NY1972]

Here is the complete result:

On Day 3 after injection of TTI-621, the patient noted a 20% reduction in the size of the injected tumor. There was a decrease in the percentage of Sézary cells (CD4+CD26-) in the peripheral blood from 56.2% before injection of TTI-621 to 26.9% on Day 3 and 5.8% on Day 5. These changes were accompanied by a transient increase in CD11b+CD14+ macrophages in the peripheral blood from 3.9% before injection to 6.1% on Day 3, which returned to baseline by Day 7. The administration of PEGylated Interferon-a2a on day 7 after TTI-621 decreased the Sézary cell count from 52.5% to 0.62% on day 14, which was accompanied by an improvement in erythroderma as well as the resolution of dysesthesia of the skin that patient experienced at baseline. A significant increase in the percentage of NK cells (CD56+CD3-) and naïve CD8+ cells (CCR7+CD45RO-) was observed following injection of TTI-621 by day 7, and also observed 7 days after PEGylated Interferon-a2a. One week following the injection of PEGylated Interferon-a2a, all tumors had regressed completely.

[NY1972]

More interesting data:

After approximately 50 days of no further treatment, the lymphoma did progress in the blood and skin, however, cutaneous tumors have not recurred

Would be nice for the SS patient to receive .2mg TTI 621 IV after IT to get rid of the residual disease as in MRD+ AML case.